Hywyn Churchill1, Harris Naina2, Richard Boriack3, Dinesh Rakheja4, Weina Chen1. 1. Department of Pathology, University of Texas Southwestern Medical Center Dallas, Texas. 2. Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center Dallas, Texas. 3. Department of Pathology and Laboratory Medicine, Children's Medical Center at Dallas Dallas, Texas. 4. Department of Pathology, University of Texas Southwestern Medical Center Dallas, Texas ; Department of Pediatrics, University of Texas Southwestern Medical Center Dallas, Texas ; Department of Pathology and Laboratory Medicine, Children's Medical Center at Dallas Dallas, Texas.
Abstract
OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma with mutations in genes encoding isocitrate dehydrogenase1 and 2 (IDH1 and IDH2). Mutant IDH generates the oncometabolite D-2-hydroxyglutarate (D-2HG). We report the first case of discordant intracellular and plasma D-2HG levels in a patient with IDH2 R172S mutated AITL. METHODS: An 87-year-old woman was diagnosed with AITL in the groin lymph node by morphologic and immunophenotypic analyses, and molecular studies by DNA sequencing. D-2HG was measured in both tumoral tissue and in pre-treatment plasma by liquid chromatography-tandem mass spectrometry. RESULTS: While D-2HG was markedly elevated in the tissue sample, its level in plasma was normal. We discuss this discordant D-2HG result within the context of previously reported discordant 2HG results in other IDH mutated tumors, and its implication for using circulating D-2HG as a biomarker of IDH mutation. In addition, this case also harbored mutations in RHOA, TET2, and TP53. The molecular pathogenesis is briefly discussed. CONCLUSION: While our case suggests that circulating D-2HG is not a reliable marker of IDH mutation in AITL, more cases need to be studied to arrive at a definite conclusion.
OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma with mutations in genes encoding isocitrate dehydrogenase1 and 2 (IDH1 and IDH2). Mutant IDH generates the oncometabolite D-2-hydroxyglutarate (D-2HG). We report the first case of discordant intracellular and plasma D-2HG levels in a patient with IDH2 R172S mutated AITL. METHODS: An 87-year-old woman was diagnosed with AITL in the groin lymph node by morphologic and immunophenotypic analyses, and molecular studies by DNA sequencing. D-2HG was measured in both tumoral tissue and in pre-treatment plasma by liquid chromatography-tandem mass spectrometry. RESULTS: While D-2HG was markedly elevated in the tissue sample, its level in plasma was normal. We discuss this discordant D-2HG result within the context of previously reported discordant 2HG results in other IDH mutated tumors, and its implication for using circulating D-2HG as a biomarker of IDH mutation. In addition, this case also harbored mutations in RHOA, TET2, and TP53. The molecular pathogenesis is briefly discussed. CONCLUSION: While our case suggests that circulating D-2HG is not a reliable marker of IDH mutation in AITL, more cases need to be studied to arrive at a definite conclusion.
Authors: Oreofe Odejide; Oliver Weigert; Andrew A Lane; Dan Toscano; Matthew A Lunning; Nadja Kopp; Sunhee Kim; Diederik van Bodegom; Sudha Bolla; Jonathan H Schatz; Julie Teruya-Feldstein; Ephraim Hochberg; Abner Louissaint; David Dorfman; Kristen Stevenson; Scott J Rodig; Pier Paolo Piccaluga; Eric Jacobsen; Stefano A Pileri; Nancy L Harris; Simone Ferrero; Giorgio Inghirami; Steven M Horwitz; David M Weinstock Journal: Blood Date: 2013-12-17 Impact factor: 22.113
Authors: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick Journal: Cancer Cell Date: 2010-12-09 Impact factor: 38.585
Authors: Rob A Cairns; Javeed Iqbal; François Lemonnier; Can Kucuk; Laurence de Leval; Jean-Philippe Jais; Marie Parrens; Antoine Martin; Luc Xerri; Pierre Brousset; Li Chong Chan; Wing-Chung Chan; Philippe Gaulard; Tak W Mak Journal: Blood Date: 2012-01-03 Impact factor: 25.476
Authors: Atsushi Terunuma; Nagireddy Putluri; Prachi Mishra; Ewy A Mathé; Tiffany H Dorsey; Ming Yi; Tiffany A Wallace; Haleem J Issaq; Ming Zhou; J Keith Killian; Holly S Stevenson; Edward D Karoly; King Chan; Susmita Samanta; DaRue Prieto; Tiffany Y T Hsu; Sarah J Kurley; Vasanta Putluri; Rajni Sonavane; Daniel C Edelman; Jacob Wulff; Adrienne M Starks; Yinmeng Yang; Rick A Kittles; Harry G Yfantis; Dong H Lee; Olga B Ioffe; Rachel Schiff; Robert M Stephens; Paul S Meltzer; Timothy D Veenstra; Thomas F Westbrook; Arun Sreekumar; Stefan Ambs Journal: J Clin Invest Date: 2013-12-09 Impact factor: 19.456
Authors: David Capper; Matthias Simon; Claus-Dieter Langhans; Jürgen G Okun; Jörg C Tonn; Michael Weller; Andreas von Deimling; Christian Hartmann Journal: Int J Cancer Date: 2011-11-02 Impact factor: 7.316
Authors: Darrell R Borger; Lipika Goyal; Thomas Yau; Ronnie T Poon; Marek Ancukiewicz; Vikram Deshpande; David C Christiani; Hannah M Liebman; Hua Yang; Hyeryun Kim; Katharine Yen; Jason E Faris; A John Iafrate; Eunice L Kwak; Jeffrey W Clark; Jill N Allen; Lawrence S Blaszkowsky; Janet E Murphy; Supriya K Saha; Theodore S Hong; Jennifer Y Wo; Cristina R Ferrone; Kenneth K Tanabe; Nabeel Bardeesy; Kimberly S Straley; Sam Agresta; David P Schenkein; Leif W Ellisen; David P Ryan; Andrew X Zhu Journal: Clin Cancer Res Date: 2014-01-29 Impact factor: 13.801
Authors: Yihong Guan; Anand D Tiwari; James G Phillips; Metis Hasipek; Dale R Grabowski; Simona Pagliuca; Priyanka Gopal; Cassandra M Kerr; Vera Adema; Tomas Radivoyevitch; Yvonne Parker; Daniel J Lindner; Manja Meggendorfer; Mohamed Abazeed; Mikkeal A Sekeres; Omar Y Mian; Torsten Haferlach; Jaroslaw P Maciejewski; Babal K Jha Journal: Blood Cancer Discov Date: 2020-12-07
Authors: François Lemonnier; Rob A Cairns; Satoshi Inoue; Wanda Y Li; Aurélie Dupuy; Sophie Broutin; Nadine Martin; Virginie Fataccioli; Romain Pelletier; Andrew Wakeham; Bryan E Snow; Laurence de Leval; Anais Pujals; Corinne Haioun; Angelo Paci; Erica R Tobin; Rohini Narayanaswamy; Katherine Yen; Shengfang Jin; Philippe Gaulard; Tak W Mak Journal: Proc Natl Acad Sci U S A Date: 2016-12-12 Impact factor: 12.779